Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 3
2010 1
2012 2
2013 1
2014 2
2015 3
2016 1
2017 3
2018 6
2019 5
2020 4
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

27 results
Results by year
Filters applied: . Clear all
Page 1
Therapeutic targeting of PP2A.
O'Connor CM, Perl A, Leonard D, Sangodkar J, Narla G. O'Connor CM, et al. Among authors: sangodkar j. Int J Biochem Cell Biol. 2018 Mar;96:182-193. doi: 10.1016/j.biocel.2017.10.008. Epub 2017 Oct 26. Int J Biochem Cell Biol. 2018. PMID: 29107183 Free PMC article. Review.
Targeting PP2A in cancer: Combination therapies.
Mazhar S, Taylor SE, Sangodkar J, Narla G. Mazhar S, et al. Among authors: sangodkar j. Biochim Biophys Acta Mol Cell Res. 2019 Jan;1866(1):51-63. doi: 10.1016/j.bbamcr.2018.08.020. Epub 2018 Sep 1. Biochim Biophys Acta Mol Cell Res. 2019. PMID: 30401535 Free PMC article. Review.
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.
Kauko O, O'Connor CM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S, Yetukuri L, Yadav B, Padzik A, Laajala TD, Haapaniemi P, Momeny M, Varila T, Ohlmeyer M, Aittokallio T, Wennerberg K, Narla G, Westermarck J. Kauko O, et al. Among authors: sangodkar j. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. doi: 10.1126/scitranslmed.aaq1093. Sci Transl Med. 2018. PMID: 30021885
Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells.
Coles GL, Cristea S, Webber JT, Levin RS, Moss SM, He A, Sangodkar J, Hwang YC, Arand J, Drainas AP, Mooney NA, Demeter J, Spradlin JN, Mauch B, Le V, Shue YT, Ko JH, Lee MC, Kong C, Nomura DK, Ohlmeyer M, Swaney DL, Krogan NJ, Jackson PK, Narla G, Gordan JD, Shokat KM, Sage J. Coles GL, et al. Among authors: sangodkar j. Cancer Cell. 2020 Jul 13;38(1):129-143.e7. doi: 10.1016/j.ccell.2020.05.003. Epub 2020 Jun 11. Cancer Cell. 2020. PMID: 32531271
Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.
Farrington CC, Yuan E, Mazhar S, Izadmehr S, Hurst L, Allen-Petersen BL, Janghorban M, Chung E, Wolczanski G, Galsky M, Sears R, Sangodkar J, Narla G. Farrington CC, et al. Among authors: sangodkar j. J Biol Chem. 2020 Jan 17;295(3):757-770. doi: 10.1074/jbc.RA119.011443. Epub 2019 Dec 10. J Biol Chem. 2020. PMID: 31822503 Free PMC article.
Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.
O'Connor CM, Leonard D, Wiredja D, Avelar RA, Wang Z, Schlatzer D, Bryson B, Tokala E, Taylor SE, Upadhyay A, Sangodkar J, Gingras AC, Westermarck J, Xu W, DiFeo A, Brautigan DL, Haider S, Jackson M, Narla G. O'Connor CM, et al. Among authors: sangodkar j. Oncogene. 2020 Jan;39(3):703-717. doi: 10.1038/s41388-019-1012-2. Epub 2019 Sep 20. Oncogene. 2020. PMID: 31541192 Free PMC article.
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.
Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky DB, Zaware N, Izadmehr S, Mazhar S, Wiredja DD, O'Connor CM, Hoon D, Dhawan NS, Schlatzer D, Yao S, Leonard D, Borczuk AC, Gokulrangan G, Wang L, Svenson E, Farrington CC, Yuan E, Avelar RA, Stachnik A, Smith B, Gidwani V, Giannini HM, McQuaid D, McClinch K, Wang Z, Levine AC, Sears RC, Chen EY, Duan Q, Datt M, Haider S, Ma'ayan A, DiFeo A, Sharma N, Galsky MD, Brautigan DL, Ioannou YA, Xu W, Chance MR, Ohlmeyer M, Narla G. Sangodkar J, et al. J Clin Invest. 2017 Jun 1;127(6):2081-2090. doi: 10.1172/JCI89548. Epub 2017 May 15. J Clin Invest. 2017. PMID: 28504649 Free PMC article.
27 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page